Market Overview

Mizuho: Time To Buy Rite Aid

Mizuho: Time To Buy Rite Aid
Related RAD
Watch These 5 Huge Put Purchases In Wednesday Trade
The Market In 5 Minutes: Wal-Mart, Cisco Disappoint Investors
Walgreens reportedly near divestiture deal (Seeking Alpha)
Related ESRX
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'
Imprimis Signs Agreement With One Of Nation's Largest Pharmacy Benefit Managers; CEO Talks Disruption
PRO Weekly Digest: Revisiting Healthcare Ideas, Plus Some Of Our Top Articles This Week (Seeking Alpha)

In a report published Wednesday, Mizuho analysts initiated coverage of Rite Aid Corporation (NYSE: RAD) with a Buy rating and price target of $10.

"We believe successful turnaround and capital restructuring efforts have set the stage for future growth through store refresh efforts, the expansion of healthcare services offerings, the refinancing of high-cost debt, and M&A," the analysts said.

The analysts believe that the potential share price catalysts include operating margin expansion, market share gains, potential future M&A and sustained optimization of the company's capital structure.

The company's efforts to achieve a turnaround have led to earnings growth, driven by rationalization of its underperforming stores, remodeling of stores, cost control and balance sheet improvement. "We think RAD is in the fifth inning of a successful operational and financial turnaround strategy," the Mizuho report stated.

In addition, the company has expanded its healthcare services with the acquisition of three healthcare services companies in the last 18 months. The analyst expect these acquisition to "drive store traffic, build customer stickiness and better position the company to the changing healthcare landscape."

The analysts also believe that Rite Aid is an attractive M&A candidate, with Express Scripts Holding Company (NASDAQ: ESRX) being a likely bidder. "Given lackluster retention rates, we think ESRX needs to make strategic moves to better position the company competitively to regain lost market share," the analysts added.

Latest Ratings for RAD

Apr 2016Deutsche BankDowngradesBuyHold
Mar 2016Credit SuisseAssumesOutperform
Jan 2016Evercore ISI GroupDowngradesBuyHold

View More Analyst Ratings for RAD
View the Latest Analyst Ratings

Posted-In: Mizuho SecuritiesAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (ESRX + RAD)

View Comments and Join the Discussion!